News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Inc. and Merck & Co. Inc. Expand Their Existing Compound Development and Supply Agreement
Boulder, Colo.– (September 12, 2000) –Array BioPharma Inc. announced today that it has expanded an existing collaboration with Merck & Co., Inc., to design and synthesize lead generation libraries for drug discovery at Merck. Under the terms of the new agreement, Merck and Array will collaborate to design small molecule libraries exclusively for Merck’s drug discovery activities. Array will develop processes for the synthesis of each library in collaboration with Merck scientists and utilize its proprietary high-speed synthesis and parallel purification platforms to create these high quality libraries. Financial terms of the deal were not disclosed.

“Our initial collaboration with Merck demonstrated Array’s ability to produce high-quality custom libraries that complement Merck’s existing inventory,” said Robert Conway, Chief Executive Officer of Array. “Array is delighted that Merck chose to expand our existing relationship.”

“After carefully evaluating companies working in this area, we have chosen to expand our collaboration with Array,” said Thomas N. Salzmann, Ph.D., Senior Vice President, Basic Research, Merck. “We are impressed by the depth of chemistry talent that Array has been able to assemble.”

Paul J. Reider, Ph.D., Merck’s Vice President of Process Research, added that “Array has an excellent team of scientists whom we expect will play an important role in both Merck's drug discovery and development activities.”

“This collaboration with Merck calls on Array’s ability to create quality structures through high-speed synthesis,” said Kevin Koch, Ph.D., Array’s President and Chief Science Officer. “We are confident that our design strategy will be effective in creating exclusive libraries that meet Merck’s high standards.”

Array BioPharma, Inc., is a privately held discovery research company providing research services in drug discovery chemistry, high throughput screening, structural biology and information management. Array complements the experience of its researchers with proprietary drug discovery tools, including unique sets of building blocks called OptimersTM for automated lead explosion, pharmacophore-biased small molecule libraries, high-speed synthesis automation, X-ray crystallography and qualifying human drug metabolism assays. For additional information, visit the company’s web site at www.arraybiopharma.com.

Merck & Co., Inc., is a global, research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products, directly and through its joint ventures, and provides pharmaceutical benefit services through Merck-Medco Managed Care.

# # #

Contact Info:

David Snitman

dsnitman@arraybiopharma.com